Cargando…

Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

The inflammasome is a molecular platform formed by activation of an innate immune pattern recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC (apoptosis-related speck-like protein containing a caspase recruitment domain), which in turn recruits procaspase-1. Proc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozaki, Ema, Campbell, Matthew, Doyle, Sarah L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303395/ https://www.ncbi.nlm.nih.gov/pubmed/25653548 http://dx.doi.org/10.2147/JIR.S51250

Ejemplares similares

NLRP3 Inflammasome and Pathobiology in AMD
por: Celkova, Lucia, et al.
Publicado: (2015)

NLRP3 Inflammasome as Therapeutic Targets in Inflammatory Diseases
por: Prakash, Annamneedi Venkata, et al.
Publicado: (2023)

Targeting the NLRP3 Inflammasome in Glaucoma
por: Coyle, Sophie, et al.
Publicado: (2021)

NLRP3 Inflammasome and Inflammatory Diseases
por: Wang, Zheng, et al.
Publicado: (2020)

Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
por: Seok, Jin Kyung, et al.
Publicado: (2021)

NLRP3 Inflammasome and Inflammatory Bowel Disease
por: Zhen, Yu, et al.
Publicado: (2019)

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
por: Xu, Congfei, et al.
Publicado: (2018)

Role of NLRP3 inflammasome in inflammatory bowel diseases
por: Tourkochristou, Evanthia, et al.
Publicado: (2019)

NLRP3 inflammasome, an immune‐inflammatory target in pathogenesis and treatment of cardiovascular diseases
por: Wang, Yucheng, et al.
Publicado: (2020)

The NLRP3 inflammasome: an emerging therapeutic target for chronic pain
por: Chen, Ruixiang, et al.
Publicado: (2021)

Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets
por: Tanase, Daniela Maria, et al.
Publicado: (2023)

Editorial: Novel perspectives on the NLRP3 inflammasome
por: Liang, Ying, et al.
Publicado: (2023)

A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases
por: Docherty, Callum AH, et al.
Publicado: (2023)

Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases
por: Shao, Bo-Zong, et al.
Publicado: (2018)

Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
por: Xu, Haowen, et al.
Publicado: (2023)

Chronic kidney disease and NLRP3 inflammasome: Pathogenesis, development and targeted therapeutic strategies
por: Huang, Gengzhen, et al.
Publicado: (2022)

Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease
por: Wu, Xiaoqin, et al.
Publicado: (2017)

Targeting the NLRP3 Inflammasome via BTK
por: Weber, Alexander N. R.
Publicado: (2021)

NLRP3 Inflammasome’s Activation in Acute and Chronic Brain Diseases—An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes
por: Chiarini, Anna, et al.
Publicado: (2023)

Neurodegenerative Disease and the NLRP3 Inflammasome
por: Holbrook, Jonathan A., et al.
Publicado: (2021)

The NLRP3-Inflammasome in Health and Disease
por: Perri, Anna
Publicado: (2022)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
por: Saresella, Marina, et al.
Publicado: (2016)

NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain
por: Silva Santos Ribeiro, Patrícia, et al.
Publicado: (2023)

NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies
por: Moltrasio, Chiara, et al.
Publicado: (2022)

The NLRP3 inflammasome: role in the pathobiology of chronic pain
por: Chen, Chen, et al.
Publicado: (2023)

The role of the NLRP3 inflammasome in gout
por: Kingsbury, Sarah R, et al.
Publicado: (2011)

NLRP3 Inflammasome Activation in Dialyzed Chronic Kidney Disease Patients
por: Granata, Simona, et al.
Publicado: (2015)

Activation of NLRP3 inflammasome in stable chronic obstructive pulmonary disease
por: Markelić, Ivona, et al.
Publicado: (2022)

NLRP3 Ubiquitination—A New Approach to Target NLRP3 Inflammasome Activation
por: Akther, Mahbuba, et al.
Publicado: (2021)

Targeting the NLRP3 Inflammasome in Severe COVID-19
por: Freeman, Tracey L., et al.
Publicado: (2020)

Targeting NLRP3 Inflammasome Activation in Severe Asthma
por: Theofani, Efthymia, et al.
Publicado: (2019)

The Role of the Effects of Autophagy on NLRP3 Inflammasome in Inflammatory Nervous System Diseases
por: Zhao, Shizhen, et al.
Publicado: (2021)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018)

Key Mechanisms and Potential Targets of the NLRP3 Inflammasome in Neurodegenerative Diseases
por: Guan, Yadi, et al.
Publicado: (2020)

Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome
por: Cantin, André M.
Publicado: (2019)

NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease
por: Zhang, Yun, et al.
Publicado: (2020)

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
por: Liang, Tao, et al.
Publicado: (2022)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

Focus on the Role of NLRP3 Inflammasome in Diseases
por: Fusco, Roberta, et al.
Publicado: (2020)

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
por: Mezzaroma, Eleonora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j5n45jd0dqfg31i6p72dtqmld9